Infarct-size limitation--real or artifactual. Studies with flurbiprofen using a reperfusion model.

Area of Science:

• Cardiovascular Research
• Pharmacology
• Histopathology

Background:

• Previous studies suggested flurbiprofen limits infarct size at 6 hours but not 24 hours post-coronary embolization in dogs.
• This discrepancy raised questions about whether the delay in infarct development was real or an artifact of the staining method.

Purpose of the Study:

• To investigate if the observed delay in infarct development by flurbiprofen is a genuine effect or an artifact of tetrazolium staining characteristics.
• To re-evaluate the efficacy of flurbiprofen in limiting myocardial infarct size in a canine model.

Main Methods:

• A closed-chest bead-embolization model was used in dogs, inducing 4 hours of myocardial ischemia.
• Radioactive microspheres (141Ce) were administered to delineate the area at risk.
• Hearts were divided into flurbiprofen (1 mg/kg every 6 hr) and saline control groups.
• Following ischemia, reperfusion was initiated, and infarct size was assessed 20 hours later using tetrazolium staining and risk zone analysis.

Main Results:

• In control hearts, 24.7% +/- 5.0% of the risk zone became necrotic.
• In flurbiprofen-treated hearts, 17.4% +/- 4.3% of the risk zone became necrotic.
• The difference in necrotic tissue between the groups was not statistically significant (p > 0.10).

Conclusions:

• Flurbiprofen did not significantly reduce infarct size in this canine model of myocardial ischemia and reperfusion.
• The previously observed delay in infarct development may be an artifact related to tetrazolium staining, not a true protective effect of the drug.